Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis

This study has been completed.
Sponsor:
Collaborator:
Solvay Pharmaceuticals
Information provided by:
Hospital Avicenne
ClinicalTrials.gov Identifier:
NCT00957151
First received: August 11, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted

August 11, 2009
August 11, 2009
April 2004
August 2005   (final data collection date for primary outcome measure)
To measure digestive and metabolic assimilation of dietary proteins in patients with chronic pancreatitis
Same as current
No Changes Posted
To determine the efficacy of enzyme therapy
Same as current
Not Provided
Not Provided
 
Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis
Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis

The objective is to evaluate the dietary nitrogen assimilation and metabolic utilisation capability of patients with chronic pancreatitis.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Pancreatitis
Drug: Creon
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
August 2005
August 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • subjects with chronic pancreatitis and taking enzyme replacement therapy

Exclusion Criteria:

  • patients with hepatic impairment
  • patients allergic to dairy proteins
  • urinary incontinence affecting the measurement of nitrogen metabolism
  • digestive disorder affecting the absorption of nutrients
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00957151
04007
Not Provided
Pr Benamouzig Robert, AP-HP
Hospital Avicenne
Solvay Pharmaceuticals
Principal Investigator: Robert Benamouzig, Pr Department of Gastroenterology
Hospital Avicenne
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP